Chest
Original Research: Diffuse Lung DiseaseThe Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis
Section snippets
Materials and Methods
This study was approved by the Area Vasta Romagna Review Board, Italy (#2614/2010). Systematic search of the patient database revealed 260 patients who satisfied the current diagnostic criteria for IPF17 seen at Pulmonary Unit, G. B. Morgagni Hospital, Forlì, Italy, during the period of January 1, 2000 to March 31, 2012. We selected 186 patients diagnosed with IPF and then followed at our institution according to a prospective protocol of clinical management that include one annual HRCT scan
Statistical Methods
Patient demographics and characteristics were compared using the two-sample rank-sum test for continuous variables and the χ2 (exact) test for categorical variables. Cumulative time-to-event distributions (survival, progression, AE) were estimated using the Kaplan-Meier method. Time-to-event outcomes were compared between the LC and non-LC groups using time-dependent proportional hazards regression models. In all cases, P values < .05 were considered statistically significant.
Patient Characteristics
Among 181 patients with IPF followed at our institution, we found 23 patients with LC-IPF (13%). Among the 23 patients with LC-IPF, seven (30%) were diagnosed as having primary pulmonary LC at the same time of IPF diagnosis. The other 16 patients (70%) developed LC 18.5 ± 23.8 months (median, 30 months; range, −27.5-84.1 months) after diagnosis of IPF during the observational period. All cases of LC were incidental findings, except for one symptomatic patient with back pain due to a vertebral
Pathology Findings
Eighty-eight patients (48.6%) had histologically proven definite UIP pattern on surgical lung biopsy (n = 84) or lung resection for LC (n = 4). The most frequently encountered histologic types of carcinomas were peripheral squamous cell (n = 9, 39%) and adenocarcinomas (n = 8, 35%). Small-cell LC was encountered for three cases (13%) and in one case was diagnosed a rare lymphoepithelioma-like large-cell LC. The remaining two cases were mixed tumor (small-cell LC with adenocarcinoma and squamous
LC Staging
Case distribution according to LC stage is reported in Figure 2. All early-stage LC (stage I, nine cases, 39%) were incidentally detected with annual HRCT scan follow-up for IPF.
LC Treatment
LC treatment according to LC TNM staging and IPF severity (gender, age, and physiology [GAP] index) is reported in Figure 2. Surgery for early LCs consisted of four lobectomies and three sublobar resections. Five patients (two lobectomies, two sublobar resections, one radiofrequency ablation) experienced a recurrence of LC after a median follow-up of 16 months (range, 13-28 months). Six of seven patients who were operated on died; survival after surgery was 20 months (1-36 months). Among four
Survival
Survival curve of patients with IPF with and without LC is displayed in Figure 3. In the group of patients with LC-IPF, 18 (78.3%) died, median survival was 38.7 months. Among the 158 patients with IPF without LC, 69 (43.7%) died (median survival, 63.9 months), and 14 (8.9%) underwent lung transplantation. One-and 3-year survivals among the two groups were 78% and 52% in the LC-IPF group and 92% and 70% in the IPF group, respectively. There was a significant difference in survival between the
Progression of IPF
Median follow-up duration was 16.2 months (range, 6.5-72.4 months) in the LC-IPF group and 40.2 months (range, 7.0-124.1 months) in the IPF group. During the follow-up period, 13 patients among 23 with LC (56.5%) and 109 among 158 without LC (69%) experienced disease progression, as previously defined. Median time-to-disease progression was 20.3 months in the LC-IPF group and 21.4 months in the IPF group. There was not a significant difference in progression-free survival between the two groups
AE of IPF
Among 61 patients experiencing AE-IPF, five were in the LC-IPF group (21.7%), and 56 were in the IPF group (35.4%). Mortality for AE was 80% (four of five) and 78.6% (44 of 56) in LC-IPF and IPF-only, respectively. In patients with LC-IPF, the AEs were triggered by medical procedure/treatment of LC in four cases (80%): two chemotherapy (of 12 patients treated, 16.7%), one lobectomy (of four lobectomies, 25%), one transbronchial biopsy (of 20, 5%).
Discussion
This study shows that in patients with IPF, LC has a significantly adverse impact on survival. Diagnosis and treatment of LC in IPF are burdened by an increased incidence of severe complicating events, apparently as lethal as the LC itself.
Including only cases with biopsy-proven LC, the prevalence of LC in our cohort of patients is 13%. Even though the suspicion of LC was high, clinicians decided not to biopsy the 3% of cases. The difficult clinical decision of declining the biopsy is driven by
Conclusions
We found a poorer survival of patients with IPF developing LC, mainly due to LC progression, and to complications of treatment. Diagnosis and treatment of LC in IPF are burdened by an increased incidence of severe complicating events, apparently as lethal as the cancer itself. Lobectomy and chemotherapy have a high incidence of lethal complicating events and their indiscriminate use in patients with LC-IPF is questionable.
Acknowledgments
Author contributions: All authors have provided final approval of the version to be published and have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. V. P. confirms that the study objectives and procedures are honestly disclosed. Moreover, he has reviewed study execution data and confirms that procedures were followed to an extent that convinces all authors
References (32)
- et al.
The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK
Respir Med
(2007) - et al.
Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema
Transl Res
(2013) - et al.
Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis
Mayo Clin Proc
(2002) - et al.
Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication?
Ann Thorac Surg
(2003) - et al.
Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection
J Thorac Cardiovasc Surg
(2003) - et al.
Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis
Ann Thorac Surg
(2011) - et al.
Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis
Lung Cancer
(2013) - et al.
The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias
Lung Cancer
(2011) - et al.
The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer
J Thorac Oncol
(2011) - et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eur J Cancer
(2009)
Lung cancer associated with usual interstitial pneumonia
Pathol Int
Cryptogenic fibrosing alveolitis and lung cancer
Thorax
Cumulative incidence of and predictive factors for lung cancer in IPF
Respirology
The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer
Respirology
Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis
Sarcoidosis Vasc Diffuse Lung Dis
Common pathways in idiopathic pulmonary fibrosis and cancer
Eur Respir Rev
Cited by (0)
Drs Tomassetti and Gurioli contributed equally.
Part of this article was presented at the ERS Annual Congress, September 24-28, 2011, Amsterdam, The Netherlands.
FUNDING/SUPPORT: This study was supported by Associazione Morgagni per le Malattie Polmonari (AMMP).
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.